Inventor · disambiguated record
John Joyal
Also filed as: JOYAL JOHN · JOYAL JOHN L
20 granted patents·5 pending applications·446 citations·filing 2001–2020
95Inventor score
Top patents by PatentIndex Score
25 records- 0197US8211402B2CA-IX specific radiopharmaceuticals for the treatment and imaging of cancerBABICH JOHN W·Filed 2009·Granted Jul 3, 2012·46 cites·33 claims
- 0296US9687572B2PSMA-targeted dendrimersBABICH JOHN W·Filed 2011·Granted Jun 27, 2017·30 cites·25 claims
- 0396US8962799B2Technetium—and rhenium-bis(heteroaryl) complexes and methods of use thereofMOLECULAR INSIGHT PHARM INC·Filed 2014·Granted Feb 24, 2015·75 cites·26 claims
- 0496US8926944B2Radiolabeled prostate specific membrane antigen inhibitorsBABICH JOHN W·Filed 2012·Granted Jan 6, 2015·60 cites·7 claims
- 0596US8840865B2Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereofMOLECULAR INSIGHT PHARM INC·Filed 2013·Granted Sep 23, 2014·32 cites·26 claims
- 0696US8211401B2Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereof for inhibiting PSMABABICH JOHN W·Filed 2009·Granted Jul 3, 2012·93 cites·20 claims
- 0795US8562945B2Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereofBABICH JOHN W·Filed 2009·Granted Oct 22, 2013·31 cites·23 claims
- 0893US8877970B2Inhibitors of carbonic anhydrase IXZIMMERMAN CRAIG·Filed 2009·Granted Nov 4, 2014·34 cites·9 claims
- 0990US9433594B2Technetium- and rhenium-bis(heteroaryl) complexes and methods of use thereofMOLECULAR INSIGHT PHARM INC·Filed 2015·Granted Sep 6, 2016·5 cites·5 claims
- 1089US9956305B2Organ protection in PSMA-targeted radionuclide therapy of prostate cancerMOLECULAR INSIGHT PHARM INC·Filed 2015·Granted May 1, 2018·8 cites·10 claims
- 1189US9447121B2Triazine based radiopharmaceuticals and radioimaging agentsMOLECULAR INSIGHT PHARM INC·Filed 2014·Granted Sep 20, 2016·10 cites·23 claims
- 1288US9120837B2Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase IXMOLECULAR INSIGHT PHARM INC·Filed 2013·Granted Sep 1, 2015·5 cites·31 claims
- 1387US9388144B2Radiolabeled prostate specific membrane antigen inhibitorsMOLECULAR INSIGHT PHARM INC·Filed 2014·Granted Jul 12, 2016·9 cites·29 claims
- 1486US10086096B2Triazine based radiopharmaceuticals and radioimaging agentsMOLECULAR INSIGHT PHARM INC·Filed 2017·Granted Oct 2, 2018·4 cites·22 claims
- 1583US10201624B2Triazine based radiopharmaceuticals and radioimaging agentsMOLECULAR INSIGHT PHARM INC·Filed 2016·Granted Feb 12, 2019·3 cites·19 claims
- 1678US10898598B2Triazine based radiopharmaceuticals and radioimaging agentsMOLECULAR INSIGHT PHARM INC·Filed 2018·Granted Jan 26, 2021·1 cites·24 claims
- 1773US11712485B2Triazine based radiopharmaceuticals and radioimaging agentsMOLECULAR INSIGHT PHARM INC·Filed 2020·Granted Aug 1, 2023·0 cites·20 claims
- 1868US10668174B2Organ protection in PSMA-targeted radionuclide therapy of prostate cancerMOLECULAR INSIGHT PHARM INC·Filed 2018·Granted Jun 2, 2020·0 cites·17 claims
- 1966US11167049B2Organ protection in PSMA-targeted radionuclide therapy of prostate cancerMOLECULAR INSIGHT PHARM INC·Filed 2020·Granted Nov 9, 2021·0 cites·17 claims
- 2055US9422251B2Metal complexes of poly(carboxyl)amine-containing ligands having an affinity for carbonic anhydrase IXMOLECULAR INSIGHT PHARM INC·Filed 2015·Granted Aug 23, 2016·0 cites·9 claims
- 2151US2003224992A1Transcription factor modulators and uses thereofPRAECIS PHARM INC·Filed 2003·Application pending·0 cites
- 2251US2010098633A1Selective seprase inhibitorsMOLECULAR INSIGHT PHARM INC·Filed 2009·Application pending·0 cites
- 2346US2009169475A1Radiolabeled derivatives of potent chymase inhibitorsMOLECULAR INSIGHT PHARM INC·Filed 2008·Application pending·0 cites
- 2445US2003045680A1Peptidic modulators of the androgen receptorPRAECIS PHARM INC·Filed 2002·Application pending·0 cites
- 2541US2002133001A1Therapeutic agents and methods of use thereof for treating an amyloidogenic diseasePRAECIS PHARM INC·Filed 2001·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →